Abstract
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Review
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Animals
-
Double-Blind Method
-
Female
-
Humans
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects*
-
Influenza Vaccines / immunology*
-
Male
-
Middle Aged
-
Placebos / administration & dosage
-
United States
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
-
Young Adult
Substances
-
FluBlok
-
Influenza Vaccines
-
Placebos
-
Vaccines, Synthetic